
|Videos|September 24, 2018
HER2+ Early-Stage Breast Cancer: Perioperative Approaches
HER2+ Early-Stage Breast Cancer: Perioperative Approaches
Advertisement
A 56-Year-Old Woman Receiving Adjuvant Therapy forHER2+ Breast Cancer
- A 56-year-old postmenopausal woman was referred for evaluation of a left-sided spiculated mass (2.4-cm) with scattered microcalcifications, found incidentally on screening mammography. Mammogram 12 months earlier was normal.
- Ultrasound confirmed a hypoechoic mass of approximately 2.4 cm X 2,3 cm by 1.8 cm at the 2 o’clock position in the left breast, 4 cm from the nipple. Axillary ultrasound demonstrated 3 enlarged lymph nodes with cortex thickening.
- Core biopsy of the breast mass revealed poorly differentiated invasive ductal carcinoma, ER/PR-negative, HER2 IHC 3+; lymph node sampling revealed the presence of breast cancer.
- Staging: T2N1M0
- She received neoadjuvant docetaxel and carboplatin with concurrent trastuzumab and pertuzumab.
- Surgical resection scattered microscopic foci of residual disease spanning 4 mm; no involved lymph nodes
- Re-staging, ypT1aypN0M0
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Roxadustat Granted Orphan Drug Designation for Myelodysplastic Syndromes
4
FDA Fast-Tracks Muzastotug Combo in MSS Metastatic Colorectal Cancer
5










































